Exploiting ligand and receptor adaptability in rational drug design using dynamics and structure-based strategies

被引:5
|
作者
LaPlante, Steven R. [1 ]
机构
[1] Boehringer Ingelheim KG, Dept Chem, Res & Dev, Laval, PQ H7S 2G5, Canada
来源
BIOACTIVE CONFORMATION I | 2007年 / 272卷
关键词
C-13; T-1; relaxation; bioactive conformation; drug design; dynamics; HCMV; HCV;
D O I
10.1007/128_2006_087
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Interactions between a biological macromolecule and a small molecule ligand involve intricate recognition events which are strongly influenced by both structure and dynamics factors. The ligand and receptor must mutually fit and adapt to each other to form a strong complex, and detailed knowledge of these factors would certainly aid drug design efforts. This work describes our experience in the characterization and exploitation of these properties within the context of two medicinal chemistry programs that targeted the essential protease enzymes of the human cytomegalovirus (HCMV) and the hepatitis C virus (HCV). Central to the rational use of such data was the qualitative elucidation of the binding parameters that defined modes/roles of each substituent of the ligands. This required the development of dynamics- and structure-based strategies that logically considered data from structure-activity relationships, NMR spectroscopy, computational chemistry, and X-ray crystallography. An important emphasis was made to monitor the relationship between inhibitor activity and ligand flexibility using C-13 NMR T, relaxation data, within the context of promoting the bioactive conformation as a drug design tool. Besides these methods which focused on data from the ligand perspective, interesting ligand-induced adaptive features of the receptors were also observed, and their impacts on drug design were explored.
引用
收藏
页码:259 / 296
页数:38
相关论文
共 50 条
  • [1] Rational structure-based drug design and optimization in the ligand-binding domain of the glucocorticoid receptor-α
    Onnis, Valeria
    Kinsella, Gemma K.
    Carta, Giorgio
    Fayne, Darren
    Lloyd, David G.
    [J]. FUTURE MEDICINAL CHEMISTRY, 2009, 1 (02) : 345 - 359
  • [2] Ligand- and Structure-Based Drug Design Strategies and PPARδ/α Selectivity
    Maltarollo, Vinicius G.
    Honorio, Kathia M.
    [J]. CHEMICAL BIOLOGY & DRUG DESIGN, 2012, 80 (04) : 533 - 544
  • [3] Structure-Based and Ligand-Based Drug Design for HER 2 Receptor
    Huang, Hung-Jin
    Lee, Kuei-Jen
    Yu, Hsin Wei
    Chen, Chien-Yu
    Hsu, Chih-Ho
    Chen, Hsin-Yi
    Tsai, Fuu-Jen
    Chen, Calvin Yu-Chian
    [J]. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2010, 28 (01): : 23 - 37
  • [4] Recent advances in structure-based rational drug design
    Gane, PJ
    Dean, PM
    [J]. CURRENT OPINION IN STRUCTURAL BIOLOGY, 2000, 10 (04) : 401 - 404
  • [5] Structure-Based Drug Design Strategies and Challenges
    Wang, Xin
    Song, Ke
    Li, Li
    Chen, Lijiang
    [J]. CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2018, 18 (12) : 998 - 1006
  • [6] Ligand- and Structure-Based Drug Design and Optimization using KNIME
    Mazanetz, Michael P.
    Goode, Charlotte H. F.
    Chudyk, Ewa, I
    [J]. CURRENT MEDICINAL CHEMISTRY, 2020, 27 (38) : 6458 - 6479
  • [7] Structure-Based Drug Design: Strategies and Challenges
    Yang, Guang-Fu
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2014, 20 (05) : 685 - 686
  • [8] STRUCTURE-BASED STRATEGIES FOR DRUG DESIGN AND DISCOVERY
    KUNTZ, ID
    [J]. SCIENCE, 1992, 257 (5073) : 1078 - 1082
  • [9] Structure-Based Rational Design of Adenosine Receptor Ligands
    Gutierrez-de-Teran, Hugo
    Sallander, Jessica
    Sotelo, Eddy
    [J]. CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2017, 17 (01) : 40 - 58
  • [10] Ligand docking for structure-based drug design.
    Jiang, X
    Venkatachalam, CM
    Oldfield, T
    Waldman, M
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1999, 217 : U697 - U697